T. Hickish

发表

Virtual reality training and assessment in laparoscopic rectum surgery

Jun J Pan, Jian Chang, Xiaosong Yang, 2015, The international journal of medical robotics + computer assisted surgery : MRCAS.

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.

T. Powles, Jenny C. Chang, T. Hickish, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

T. Hickish, C. Boni, J. Tabernero, 2004, The New England journal of medicine.

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

Mike J. Irwin, James D. Brenton, Carlos Caldas, 2016, Breast Cancer Research.

Small-cell lung cancer: Report of a Meeting of POhysicians and Scientists at the Royal Marsden Hospital, Sutto, UK

T. Eisen, T. Hickish, J. Sloane, 1995 .

Small-cell lung cancer Report of a Meeting of POhysicians and Scientists at the Royal Marsden Hospital, Sutto, UK

T. Eisen, T. Hickish, J. Sloane, 1995, The Lancet.

Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006

T. Hickish, C. Pritchard, Colin Pritchard, 2011, British Journal of Cancer.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

Christian Jacques, Lucile Awad, David Cunningham, 1998, The Lancet.

Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.

T. Hickish, R. Ott, D. Cunningham, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.

T. Hickish, A. Norman, D. Tait, 2005, European journal of cancer.

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.

T. Hickish, D. Tait, J. Tabernero, 2015, International journal of radiation oncology, biology, physics.

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.

T. Hickish, D. Cunningham, I. Chau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial

C. Caldas, E. Provenzano, J. Abraham, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.

A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial.

R. Laing, T. Hickish, S. Ebbs, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2017, The Lancet. Oncology.

Changes in cancer incidence and mortality in England and Wales and a comparison of cancer deaths in the major developed countries by age and sex 1979–2002 in context of GDP expenditure on health

T. Hickish, C. Pritchard, 2008, Ecancermedicalscience.

Tamoxifen therapy and carcinogenic risk.

T. Powles, T. Hickish, 1995, Journal of the National Cancer Institute.

Glucose Intolerance During Adjuvant Chemotherapy for Breast Cancer

T. Hickish, D. Kerr, D. Sheriff, 2016 .

Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

T. Hickish, S. Gwyther, P. Quirke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

C. Tournigand, T. Hickish, C. Boni, 2010 .

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

T. Hickish, A. Norman, D. Tait, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

T. Hickish, A. Norman, D. Tait, 2003, British Journal of Cancer.

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.

T. Hickish, E. Van Cutsem, E. Cutsem, 1999, European journal of cancer.

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

A. Briggs, T. Hickish, J. Tabernero, 2018, British Journal of Cancer.

Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum

T. Hickish, B. Moran, M. Chand, 2012, Annals of the Royal College of Surgeons of England.

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

T. Hickish, A. Norman, M. Nicolson, 2005, British Journal of Cancer.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

T. Hickish, C. Boni, J. Tabernero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years

T. Hickish, C. Boni, J. Tabernero, 2005 .

Patient preference for extended palliative chemotherapy for non-small cell lung cancer

T. Hickish, M. Nicolson, I. Smith, 1995, The Lancet.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Colorectal tubulovillous adenomas identified on fluoro‐2‐deoxy‐d‐glucose positron emission tomography/computed tomography scans

T. Hickish, A. Hemandas, N. Robson, 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

T. Powles, J. Kanis, T. Hickish, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for elderly patients with lung cancer

T. Hickish, I. Smith, G. Middleton, 1995, The Lancet.

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.

M. Gore, T. Hickish, J. Sloane, 1996, British Journal of Cancer.

Breast cancer response to hormone replacement therapy withdrawal

T. Powles, T. Hickish, 1995, The Lancet.

Hormone replacement after breast cancer

T. Powles, T. Hickish, M. O'Brien, 1993, The Lancet.

A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results

M. Gore, T. Hickish, M. Nicolson, 1998, British journal of haematology.

High-dose melphalan for multiple myeloma: long-term follow-up data.

M. Gore, T. Hickish, M. Nicolson, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer

P. Mohanty, T. Hickish, R. Kurzrock, 2018, Oncoimmunology.

Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR).

C. Caldas, E. Provenzano, H. Earl, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab.

E. Winer, T. Hickish, N. Lin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature

T. Hickish, E. U. Cidon, P. A. Martínez, 2018, World journal of clinical cases.

Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer

T. Hickish, A. Norman, M. Nicolson, 1999 .

Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.

T. Hickish, D. Cunningham, J. Husband, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.

T. Hickish, M. Nicolson, L. Paz-Ares, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.

T. Hickish, S. Johnston, I. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years

T. Hickish, C. Boni, J. Tabernero, 2007 .

Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

P. Beale, T. Hickish, I. Judson, 1998, Cancer Chemotherapy and Pharmacology.

Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases.

T. Hickish, O. Garden, D. Cunningham, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

randomised, multicenter phase-iii study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation : 1031

T. Hickish, A. Norman, M. Nicolson, 2003 .

Gastrointestinal non-Hodgkin's lymphoma.

T. Hickish, D. Cunningham, 1990, Bailliere's clinical gastroenterology.

POLYMERASE CHAIN REACTION FOR DETECTION OF DISSEMINATION IN GASTRIC LYMPHOMA

T. Hickish, D. Cunningham, P. Isaacson, 1989, The Lancet.

FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial.

T. Hickish, C. Boni, J. Tabernero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DETECTING t(14;18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE

T. Hickish, D. Cunningham, 1989, The Lancet.

The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma.

T. Hickish, J. Sloane, D. Cunningham, 1993, British Journal of Cancer.

FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.

C. Tournigand, T. Hickish, C. Boni, 2010 .

Management of colorectal cancer and diabetes

T. Hickish, Caroline Yao, G. Nash, 2014, Journal of the Royal Society of Medicine.

A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.

T. Hickish, J. Gardner-Thorpe, D. Cunningham, 2013 .

Calcipotriol and regression in T-cell lymphoma of skin

T. Hickish, J. Sloane, D. Cunningham, 1993, The Lancet.

Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial

T. Hickish, D. Cunningham, J. Bridgewater, 2017 .

TECHNOLOGY A Review on Pressure Ulcer: Aetiology, Cost, Detection and Prevention Systems

Mahbub C. Mishu, T. Hickish, V. Dubey, 2014 .

Vitamin D deficiency and muscle strength in male alcoholics.

T. Hickish, J. Bland, J. Maxwell, 1989, Clinical science.

Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials

T. Hickish, A. Norman, J. Black, 2006, British Journal of Cancer.

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.

P. Mohanty, T. Hickish, L. Wyrwicz, 2017, The Lancet. Oncology.

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.

T. Lister, A. Oza, T. Hickish, 1993, British Journal of Cancer.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

A. Briggs, T. Hickish, J. Tabernero, 2018, The Lancet. Oncology.

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.

M. Gore, T. Hickish, M. Nicolson, 1996, British Journal of Cancer.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

T. Hickish, J. Cassidy, I. Macpherson, 2014, European journal of cancer.

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.

T. Hickish, A. Norman, M. Nicolson, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)

Mano, E. Perez, H. Gómez, 2013 .

Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2.

T. Hickish, P. Clarke, M. Hill, 1994, Cancer research.

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.

T. Hickish, I. Pedley, Robert J. Jones, 2014, Future oncology.

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

T. Hickish, A. Norman, M. Nicolson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

T. Hickish, A. Norman, M. Nicolson, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Harpreet Wasan, Tamas Hickish, Ayman Madi, 2011, The Lancet. Oncology.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.

W. Scheithauer, T. Hickish, J. Tabernero, 2013 .

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

A. Schneeweiss, T. Hickish, J. Cortes, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

EPIC: an effective low toxicity regimen for relapsing lymphoma.

M. Gore, T. Hickish, D. Catovsky, 1993, British Journal of Cancer.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

T. Hickish, W. Greenhalf, Eithne Costello, 2014, The Lancet. Oncology.

Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.

T. Hickish, D. Cunningham, J. Mansi, 1991, British Journal of Cancer.

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.

T. Hickish, A. Norman, D. Cunningham, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

R. Gelber, J. Baselga, T. Hickish, 2019, European journal of cancer.

Perforated Duodenal Ulcer and Cigarette Smoking

T. Hickish, C. Wastell, C. Yale, 1988, Journal of the Royal Society of Medicine.

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

T. Hickish, M. Nicolson, D. Talbot, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

Xidong Jin, Chiun-Sheng Huang, T. Hickish, 2022, Breast Cancer Research and Treatment.

Stem Cells in Colon Cancer

T. Hickish, E. U. Cidon, 2014 .

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

R. Laing, C. Caldas, E. Provenzano, 2014, The Lancet. Oncology.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

T. Hickish, R. Butler, O. Garden, 2014, The Lancet. Oncology.

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

T. Powles, T. Hickish, A. Makris, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

L. Carey, T. Hickish, M. Uttenreuther-Fischer, 2009 .

A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer.

T. Hickish, A. Norman, M. Nicolson, 1998, British Journal of Cancer.

Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.

T. Hickish, A. Norman, M. Nicolson, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

T. Hickish, W. Greenhalf, Eithne Costello, 2017, The Lancet. Oncology.

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

T. Hickish, A. Norman, M. Nicolson, 1999, British Journal of Cancer.

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

T. Hickish, A. Norman, M. Nicolson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

M. Dowsett, P. Ellis, T. Hickish, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.

A. Schneeweiss, T. Hickish, S. Chia, 2018, European journal of cancer.

A midline for oxaliplatin infusion: the myth of safety devices

T. Hickish, E. Uña Cidón, B. Masters, 2014, BMJ Case Reports.

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Tamas Hickish, Pamela Munster, Eric P. Winer, 2012, Breast Cancer Research and Treatment.

A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder

T. Hickish, D. Heathcote, S. Thompson, 2014, Psycho-oncology.

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.

T. Hickish, A. Norman, M. Nicolson, 2006, European journal of cancer.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

The role of cardiac biomarkers in early detection of cardiotoxicity in breast cancer treated with trastuzumab in the adjuvant setting: a systematic review

T. Hickish, E. U. Cidon, P. Alonso, 2021 .

Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.

T. Hickish, D. Catovsky, D. Cunningham, 1994, Leukemia & lymphoma.

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.

T. Hickish, I. Smith, G. Middleton, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-steroidal anti-inflammatory drugs and peptic ulcer perforation.

T. Hickish, F. Smedley, 1986, Gut.

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

R. Laing, T. Hickish, S. Ebbs, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.

R. Laing, A. Howell, T. Hickish, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

A. Briggs, T. Hickish, J. Tabernero, 2019, Health technology assessment.

T. Hickish, C. Boni, J. Tabernero, 2009 .

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

Jacob G. Scott, H. J. Pearson, C. Fuller, 2012 .

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.

L. Assersohn, T. Hickish, A. Norman, 2003, European journal of cancer.

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.

T. Hickish, A. Norman, D. Cunningham, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

T. Hickish, N. Heaton, O. Garden, 2020, The Lancet. Oncology.

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer.

T. Hickish, M. Hubank, A. Wardley, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

C. Caldas, E. Provenzano, J. Abraham, 2017, Modern Pathology.

Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors.

T. Hickish, I. Smith, G. Middleton, 1998, British Journal of Cancer.

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

T. Hickish, A. Wotherspoon, D. Cunningham, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.

T. Hickish, A. Norman, M. Nicolson, 1995, European journal of cancer.

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer

T. Hickish, D. Cunningham, I. Chau, 2017, World journal of gastrointestinal oncology.

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.

T. Hickish, S. Joel, M. Nicolson, 1997, British Journal of Cancer.

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

T. Hickish, A. Norman, D. Cunningham, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Somatostatin imaging function

V. R. McCready, T. Hickish, 1994, The Lancet.

Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study

F. Percival, T. Hickish, S. Houston, 2010, Journal of medical economics.

Experience with intermediate-dose (110–120 mg/m2) epirubicin

R. Coombes, T. Hickish, D. Cunningham, 2004, Cancer Chemotherapy and Pharmacology.

Comparing UK and 20 Western countries' efficiency in reducing adult (55–74) cancer and total mortality rates 1989–2010: Cause for cautious celebration? A population-based study

T. Hickish, Mark S. Wallace, C. Pritchard, 2016, JRSM open.

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study

T. Hickish, O. Garden, D. Cunningham, 2016, British Journal of Cancer.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).

A. Schneeweiss, T. Hickish, J. Cortes, 2011 .

Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.

S. Singhal, J. Mehta, T. Hickish, 1996, Leukemia & lymphoma.

Abstract PD2-3: ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer

C. Caldas, E. Provenzano, J. Abraham, 2015 .

LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L).

Chiun-Sheng Huang, T. Hickish, M. Uttenreuther-Fischer, 2012 .

Increased DNA Methylation of ABCB1, CYP2D6, and OPRM1 Genes in Newborn Infants of Methadone‐Maintained Opioid‐Dependent Mothers

T. Hickish, H. Mactier, A. Parker, 2017, The Journal of pediatrics.

502PDMOSAIC STUDY: ACTUALIZATION OF OVERALL SURVIVAL (OS) WITH 10 YEARS FOLLOW UP AND EVALUATION OF BRAF. BY GERCOR AND MOSAIC INVESTIGATORS.

W. Scheithauer, T. Hickish, A. Duval, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK

T. Hickish, C. Pritchard, 2011, The Lancet.

Graphic and haptic simulation system for virtual laparoscopic rectum surgery

Jian Chang, Robert Howell, Tamas Hickish, 2011, The international journal of medical robotics + computer assisted surgery : MRCAS.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

T. Hickish, H. Wasan, T. Maughan, 2011, The Lancet. Oncology.

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.

Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial

T. Hickish, A. Wardley, N. Turner, 2023, Cancer Research.

INTELLIGENT AGENT BASED SOFTWARE ARCHITECTURE OF A WEARABLE ELECTROTACTILE FEEDBACK SYSTEM FOR BALANCE IMPROVEMENT

Venketesh N. Dubey, Jonathan Cole, Jan Walter Schroeder, 2014 .

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

T. Hickish, H. Wasan, T. Maughan, 2011, The Lancet. Oncology.

Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.

T. Hickish, A. Norman, D. Tait, 2004, Clinical colorectal cancer.

Post-Traumatic Stress Disorder in Cancer Survivors: Recognising and Acknowledging the Symptoms

T. Hickish, S. Thompson, L. Eccleston, 2011 .

Longitudinal study of energy and macronutrient intake during the first year following treatment for early stage breast cancer

T. Hickish, J. Jeffery, J. Hewitt-Taylor, 2018, Proceedings of the Nutrition Society.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

T. Hickish, W. Greenhalf, P. Ghaneh, 2017, The Lancet. Oncology.

A. Schneeweiss, T. Hickish, S. Chia, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Mathematical Modelling of Different Types of Body Support Surface for Pressure Ulcer Prevention

Venketesh N. Dubey, Jonathan Cole, Tamas Hickish, 2014 .

Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.

T. Hickish, Janine Mansi, H. Purvies, 1991, British Journal of Cancer.

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

T. Hickish, M. Dobson, A. Wotherspoon, 2012, The Lancet. Oncology.

T. Hickish, A. Norman, M. Nicolson, 2005, British Journal of Cancer.

A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes

T. Hickish, P. Barrett-Lee, A. Davies, 2020 .

E. Provenzano, J. Abraham, T. Hickish, 2015, The Lancet. Oncology.

ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR)

C. Caldas, E. Provenzano, J. Abraham, 2014 .